Terri Childers was told she would die from her cancer.
Late 2023. Triple-negative breast cancer. Already spread to her chest and lungs.
Her doctors said it plainly: we'll try to buy you time.
That was the old script for this disease.
This week, that script got torn up.
The FDA just greenlit a second new drug for advanced triple-negative breast cancer — the most aggressive, hardest-to-treat form of the disease.
Gilead's Trodelvy got the nod on June 24.
AstraZeneca and Daiichi Sankyo's Datroway got there first, in May.
Two approvals. One month apart. After decades of almost zero breakthroughs.
These aren't ordinary chemotherapy drugs.
They're antibody-drug conjugates — think of them as guided missiles.
The result?
📉 Around 40% lower risk of the cancer progressing vs. standard chemo.
📈 Datroway extended median survival by 5 months.
Triple-negative breast cancer doesn't wait.
It recurs and spreads in about 2.5 years — half the time of other breast cancers.
Median survival in the advanced stage? Less than two years.
And here's the brutal part:
👉 About half of patients never even get a second treatment.
Which means the first drug you're handed isn't just important.
It's often the only real shot.
Around 48,000 Americans were diagnosed last year.
Disproportionately younger women. Disproportionately Black and Latina women.
This isn't a disease of old age. It's a disease of mothers in their 30s and 40s.
Analysts are watching closely:
The two haven't been tested head-to-head. Doctors can't yet say which wins.
But patients suddenly have choices they never had before.
She enrolled in Gilead's trial in January 2024.
By March, her tumors were shrinking.
Mastectomy. 44 rounds of radiation. A recurrence. Back on Trodelvy plus Keytruda.
By May 2026, scans showed the cancer still retreating.
She spends her good days at her grandkids' baseball games and dance recitals.
She hasn't missed one yet.
That's what a 40% number looks like in real life.
That's all for now!
